Literature DB >> 6172387

Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines.

S A Ben-Sasson, G Klein.   

Abstract

Recent studies indicate that gene expression in higher eukaryotes is accompanied by a decrease in the frequency of 5-methyl cytosine residues around the activated site (Razin and Riggs, 1980). 5-aza-cytidine (5-aza-C) is an analogue that reduces cytidine methylation in DNA (Jones and Taylor, 1980) and has been reported to change the differentiation pattern of cultured mouse embryo cells (Taylor and Jones, 1979). We have tested its ability to activate the Epstein-Barr virus cycle in latently EBV-infected human lymphoid lines. After an incubation period of 6 to 8 h with the drug, early antigens (EA) were induced in a substantial fraction of the cells in all six lines tested that had a low rate of spontaneous viral antigen production. Optimal conditions for EA induction were defined. The efficiency of 5-aza-C was comparable to the inducing effect of iododeoxyuridine. EBV-DNA and EBNA positive virus-non-producer lines did not respond to 5-aza-C treatment. The findings are discussed in relation to the possibility that changes in EBV-gene expression may be related to the state of DNA methylation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6172387     DOI: 10.1002/ijc.2910280204

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

1.  The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus.

Authors:  D Zerby; C J Chen; E Poon; D Lee; R Shiekhattar; P M Lieberman
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

2.  Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.

Authors:  L Yoo; S H Speck
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta.

Authors:  Yao Chang; Heng-Huan Lee; Shih-Shin Chang; Tsuey-Ying Hsu; Pei-Wen Wang; Yu-Sun Chang; Kenzo Takada; Ching-Hwa Tsai
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells.

Authors:  Zhen Lin; Kenneth Swan; Xin Zhang; Subing Cao; Zoe Brett; Stacy Drury; Michael J Strong; Claire Fewell; Adriane Puetter; Xia Wang; MaryBeth Ferris; Deborah E Sullivan; Li Li; Erik K Flemington
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

5.  Growth of B95-8 cells and expression of Epstein-Barr virus lytic phase in serum-free medium.

Authors:  J E Shaw; R G Petit; K Leung
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

6.  De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.

Authors:  Jianjiang Ye; Lyndle Gradoville; Derek Daigle; George Miller
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

7.  Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus.

Authors:  Jill Countryman; Lyndle Gradoville; Sumita Bhaduri-McIntosh; Jianjiang Ye; Lee Heston; Sarah Himmelfarb; Duane Shedd; George Miller
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

8.  Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome.

Authors:  M Thurnher; S Rusconi; E G Berger
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.

Authors:  Jianqing Lin; Jill Gilbert; Michelle A Rudek; James A Zwiebel; Steve Gore; Anchalee Jiemjit; Ming Zhao; Sharyn D Baker; Richard F Ambinder; James G Herman; Ross C Donehower; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.